Skip to main content
. 2015 Nov 3;6(36):38469–38486. doi: 10.18632/oncotarget.6288

Figure 10. Sensitivity of neuroblastoma cell lines to LIMK inhibition.

Figure 10

A. Cell viability relative to DMSO vehicle control was determined by CellTiter-Glo® after treatment of neuroblastoma cell lines with indicated concentrations of LIMKi. Figure legend shows the calculated EC50 for each cell line (mean + SEM, n = 3). B. Comparison of the sensitivities of 27 neuroblastoma cell lines to CRT0105950 and CRT0105446 with the sensitivity of 6 neuroblastoma cell lines to LIMKi. Line indicates mean EC50 for each LIMK inhibitor. Significance was analyzed by one-way ANOVA and post-hoc Tukey's test. C. SK-N-AS and SK-N-SH neuroblastoma cell lines were left untreated or transfected with non-targeting (NTC) siRNA, a combination of LIMK1 and LIMK2 siRNAs (LIMK1+LIMK2) or a dual LIMK1/LIMK2 targeting siRNA as indicated, then 72 hours later cell lysates were prepared and immunoblotted for LIMK1 and LIMK2. αTubulin blotting allowed for comparison of protein loading. D. Relative cell viability was determined for SK-N-AS and E. SK-N-SH cells 72 hours after siRNA transfection by CellTiter-Glo® viability assay and normalized to untransfected cells in each experimental replicate. Significance was analyzed by one-way ANOVA and post-hoc Tukey's test.